Inactive Instrument

DEINOVE

ALDEI

FR0010879056

Deinove SA Announces Consolidated Financial Results for the Year Ended December 31, 2020

March 25, 2021 at 12:45 pm EDT

Deinove SA announced consolidated financial results for the year ended December 31, 2020. For the year, operating revenues were EUR 836,000 against EUR 637,000 for the last year. Operating loss was EUR 8,125,000 against EUR 12,201,000 for the last year. Consolidated loss was EUR 7,300,000 against EUR 10,247,000 for the last year.

Latest news about DEINOVE

Deinove SA(ENXTPA:ALDEI) dropped from Next Biotech Index	23-04-11	CI
Court Reserves Decision On Deinove Receivership Proceedings	23-01-16	MT
Deinove SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-10-06	CI
Deinove SA Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-08	CI
Deinove SA Announces the Extension of Its Clinical Trial to Canada	22-04-07	CI
DEINOVE Appoints Michael MOUREZ as Chief Innovation Officer	22-03-17	CI
Deinove SA Announces A Favorable Opinion from the DSMBfor the Continuation of the Phase II Clinical Trial of DNV3837 in Clostridioides Difficile Infections	22-01-06	CI
Deinove SA announced that it expects to receive €10 million in funding from L1 Capital Pty. Limited	21-08-31	CI
Deinove Announces Collaboration with Max Mousseron Institute of Biomolecules and the LMP of the University of Montpellier	21-06-30	CI
Global markets live: Nestlé, Schindler, Credit Suisse	21-04-30
Deinove SA Announces Consolidated Financial Results for the Year Ended December 31, 2020	21-03-25	CI
Deinove Benefits from the Support of the French Government, Within the Framework of the France Relance Plan, to Accelerate the Development of New Antimicrobials	21-03-10	CI
Deinove SA Appoints Hervé Ansanay as Director	21-01-21	CI
Deinove SA Executive Changes	21-01-11	CI
Deinove SA Signs an Evaluation and Technology Development License with DSM	20-11-19	CI
Deinove Sa Reports Earnings Results for the Half Year Ended June 30, 2020	20-09-30	CI
DEINOVE Pursues Phase II Clinical Trial of its Antibiotic Candidate DNV3837	20-07-15	CI
DEINOVE Appoints Alexis Rideau as CEO, Effective May 1, 2020	20-05-04	CI
Deinove Sa Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-29	CI
DEINOVE Announces the Official Launch of Luminity	20-04-23	CI
DEINOVE Provides Update on BIOME Oléoactif	20-03-18	CI
Deinove SA Expands its Range of Cosmetic Active Ingredients	20-02-19	CI
Sharon Laboratories Capitalizes on Deinove to Sustain Its Development Activities	20-02-06	CI
DEINOVE Announces the Inclusion of the First Patient in the Phase II Trial Testing DNV3837	20-01-27	CI
DEINOVE Announces the Production of New Industrial Batch of Phyt-N-Resist	20-01-22	CI

Chart DEINOVE

Duration

Period

More charts

Company Profile

DEINOVE is a French biotechnology company pioneering the exploration of a new domain of life, unexplored at 99.9%: the "microbial dark matter". By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance. The new therapies discovered and developed by DEINOVE target superbugs (microbes that have become resistant to one or more antimicrobials) that cause life-threatening infections which are now spreading at high speed. Nowadays, DEINOVE is conducting several development programs, of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infections, one of the World primary emergencies.

Sector

Renewable Fuels

More about the company